Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Deferred Revenue: 2016-2023

Historic Current Deferred Revenue for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2023 value amounting to $7.7 million.

  • Seres Therapeutics' Current Deferred Revenue rose 181.22% to $7.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.9 million, marking a year-over-year increase of 181.22%. This contributed to the annual value of $7.7 million for FY2023, which is 81.50% up from last year.
  • Per Seres Therapeutics' latest filing, its Current Deferred Revenue stood at $7.7 million for FY2023, which was up 81.50% from $4.3 million recorded in FY2022.
  • Seres Therapeutics' 5-year Current Deferred Revenue high stood at $22.6 million for FY2020, and its period low was $4.3 million during FY2022.
  • Over the past 3 years, Seres Therapeutics' median Current Deferred Revenue value was $7.7 million (recorded in 2023), while the average stood at $9.6 million.
  • Per our database at Business Quant, Seres Therapeutics' Current Deferred Revenue plummeted by 74.68% in 2022 and then soared by 81.50% in 2023.
  • Yearly analysis of 5 years shows Seres Therapeutics' Current Deferred Revenue stood at $21.0 million in 2019, then climbed by 7.83% to $22.6 million in 2020, then fell by 25.59% to $16.8 million in 2021, then slumped by 74.68% to $4.3 million in 2022, then spiked by 81.50% to $7.7 million in 2023.